MDX-1097 (also called IST-1097 or KappaMab) is a monoclonal antibody therapy being assessed in Phase IIb clinical trials as a treatment for multiple myeloma, a type of white blood cell cancer. It is a chimeric version of the mouse monoclonal antibody K-1-21. MDX-1097 targets kappa free immunoglobulin light chains which are found on the surface of some kappa light chain-restricted myeloma cells. MDX-1097 was originally developed by scientists at Immune System Therapeutics Ltd. In 2015, Haemalogix Pty Ltd acquired the rights to MDX-1097 and are now taking it through late stage clinical testing.
Attributes | Values |
---|---|
rdf:type |
|
rdfs:label |
|
rdfs:comment |
|
dcterms:subject | |
Wikipage page ID |
|
Wikipage revision ID |
|
Link from a Wikipage to another Wikipage | |
sameAs | |
dbp:wikiPageUsesTemplate | |
CAS number |
|
synonyms |
|
type |
|
has abstract |
|
gold:hypernym | |
prov:wasDerivedFrom | |
page length (characters) of wiki page |
|
CAS number |
|
foaf:isPrimaryTopicOf | |
is Link from a Wikipage to another Wikipage of | |
is Wikipage redirect of | |
is foaf:primaryTopic of |